Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
NGENLA (Pfizer Australia Pty Ltd)
Product name
NGENLA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
182 (255 working days)
Active ingredients
somatrogon
Registration type
NCE/NBE
Indication
NGENLA (solution for injection) is indicated for the long-term treatment of paediatric patients with growth disturbance due to insufficient secretion of growth hormone.